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Monoclonal gammopathy  
with renal significance
ABSTRACT
Monoclonal gammopathy of unknown significance (MGUS) is a benign condition that carries a risk of pro-
gression to haematological malignancy. It is accepted that MGUS should not be treated until progression 
to multiple myeloma or another lymphoid malignancy. Recently, growing evidence has started to show that 
even small monoclonal clones can be responsible for renal impairment. Long-term observation of patients 
with monoclonal gammopathy and abnormal renal function showed that this condition can significantly 
affect renal and overall survival. Patients with monoclonal gammopathy with renal impairment have also 
higher risk of relapse after kidney transplantation. Among patients with monoclonal gammopathy of un-
known significance there is a group of defined monoclonal component-related diseases, which includes: 
light-chain amyloidosis, monoclonal immunoglobulin deposition disease, crystal-storing histiocytosis, 
cryoglobulinaemias, and some others. They can be diagnosed on the base of clinical features and on 
histological examination. In patients with monoclonal protein and deposition of fragments or whole particle 
of monoclonal immunoglobulin with distinct localisation and substructural organisation can be found. 
The treatment strategy is targeting of B cell clones, which requires administration of chemotherapeutics 
or other medications that are used for the treatment of lymphoid malignancy or myeloma. The choice of 
therapeutic agent should take into account the current kidney status. Treatment of renal disease should 
not differ from other patients with similar conditions not related to monoclonal protein. The expert opinion 
is that the presence of monoclonal gammapathy is not a contraindication to kidney transplantation.
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Introduction
Monoclonal gammopathy of unknown significance 
(MGUS) is defined by a monoclonal immunoglobulin 
in serum and 10% or fewer plasma cells in the bone 
marrow, in persons without evidence of multiple my-
eloma, amyloidosis, or other lymphoproliferative B-cell 
disorders [1, 2]. it is a benign condition that carries 
a risk of progression to a haematological malignan-
cy. The probability of developing multiple myeloma, 
waldenstrom’s macroglobulinaemia, amyloidosis, or 
any other lymphoproliferative disorder in patients with 
MGUS is approximately 1% per year [2]. it is generally 
accepted that the condition should not be treated until 
progression to multiple myeloma with organ damage, 
or other lymphoid malignancies. Nephrotic complica-
tions in patients with multiple myeloma usually result 
from cast nephropathy, which is caused by excessive 
production of light chains. High tumour mass does not 
necessarily increase the risk of kidney damage [3]. The 
evidence from animal experiments shows that injection 
of even a small amount of Bence–Jones protein isolated 
from serum of myeloma patients can induce cast ne-
phropathy [4]. There is a growing amount of evidence 
that proves that even small monoclonal clones can be 
responsible for renal impairment in affected patients [5]. 
Despite their non-malignant nature they can cause 
significant morbidity or even premature death. The 
affected patients are still diagnosed as having MGUS, 
but the presence of monoclonal protein is no longer un-
known. To avoid confusion, the term glomerulonephritis 
with MGUS or monoclonal immunoglobulin deposition 
disease (MiDD) with MGUS started to be replaced by 
the term monoclonal gammopathy of renal significance 
(MGrS) [6]. Despite evidence that links the presence 
of monoclonal immunoglobulin in serum to kidney im-
pairment, many patients with monoclonal gammopathy, 
not fulfilling the criteria of myeloma, remain untreated or 
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undertreated. in a published report from italy, among 
patients diagnosed with light chain deposition disease 
with renal involvement, more than a quarter did not 
receive any treatment [7]. in another report from Mayo, 
the long-term observation of patients with the same 
diagnosis showed that the overall five-year survival rate 
was only 70%. The five-year renal survival was 37% [8]. 
what is worse, patients with MGrS are at higher risk of 
relapse after kidney transplantation [9, 10].
Apart from monoclonal gammopathy of unknown 
significance there is a group of defined monoclonal 
component diseases which if left untreated may cause 
irreversible kidney damage or may even be fatal. They 
include light-chain (AL) amyloidosis, monoclonal 
immunoglobulin deposition disease, crystal-storing 
histiocytosis, and cryoglobulianemias. 
Diagnosis
Microscopic examination
in most cases MGrS results from deposition of frag-
ments or whole particles of monoclonal immunoglobulin 
in distinct localisations and substructural organisation. 
They can aggregate causing glomerulopathies with 
organised amyloid fibrils or microtubular deposits as 
well as form punctate aggregates, produce crystals, or 
cause vascular obstruction [5]. Amyloid fibrils are most 
commonly seen in AL amyloidosis, immunoglobulin 
heavy chain, or immunoglobulin light and heavy chain 
amyloidosis [11]. Microtubular monoclonal immuno-
globulin deposits, which are responsible for vascular 
obstruction in small vessels, are usually seen in type i 
and type ii cryoglobulinaemias or immunocytoid glo-
merulopathy. Non-organised deposits (randal and 
non-randal type) are observed in patients with mono-
clonal immunoglobulin deposition disease or in prolif-
erative glomerulonephritis with deposits of monoclonal 
immunoglobulins [12, 13]. Monoclonal gammopathy 
of renal significance can be responsible for the tubular 
defect present in Fanconi syndrome [14]. in this case 
the defect is caused by crystal deposits.
Clinical features
The results of the study performed in Mayo showed 
that more than half of the patients with monoclonal 
gammopathy had renal lesions that were directly relat-
ed to the presence of monoclonal protein [15]. Other 
causes included diabetic nephropathy, focal segmental 
glomerulosclerosis, and arterionephrosclerosis. There-
fore, the diagnosis of MGrS should be based on the 
detection of monoclonal protein in the kidney. renal 
biopsy should be performed for every patient with the 
presence of monoclonal protein, renal insufficiency, and 
severe proteinuria. immunofluorescence and electron 
microscopy are essential to establish the type of heavy 
and light chain monoclonal immunoglobulin deposits 
in the kidney, as well as the pattern of their organisa-
tion [16]. immunofixation and protein electrophoresis 
should be performed. if serum or urine immunofixation 
is negative for monoclonal protein, measurement of se-
rum free light chain ratio can help with diagnosis. Bone 
marrow examination is also an essential part of the 
diagnostic process. Plasmocyte or lymphocyte clonality 
should be established. The type of monoclonal protein 
should be the same as that found in renal deposits and 
in serum [6]. 
in many cases of MGrS the clinical diagnosis is of 
AL amyloidosis — a progressive condition characterised 
by tissue and organ amyloid deposits. it is usually as-
sociated with small numbers of clonal plasma cells that 
produce l light chains present in the bone marrow [17]. 
The general symptoms include weight loss, fatigue, or 
oedema. On physical examination, characteristic abnor-
malities include enlargement of the tongue, periorbital 
purpura, or periarticular amyloid infiltration. Patients 
with amyloidosis may also present with hepatomegaly 
or carpal tunnel syndrome [18].The most commonly 
affected organs are: kidney, heart, and liver as well as 
the peripheral and autonomic nervous systems. At the 
time of diagnosis nephrotic syndrome is present in 50% 
of patients, and kidney failure in 18% of patients [5]. The 
diagnosis of AL should always be confirmed by biopsy. 
The recommended procedure for this is a fine-needle 
aspiration of abdominal fat or minor labial salivary gland. 
The liver or kidney should be considered as organs 
of second choice for biopsy because of minor risk of 
bleeding [18, 19]. Amyloid deposits stain positive with 
Congo red and demonstrate apple-green birefringence 
under polarised light [20]. 
Monoclonal immunoglobulin deposition disease 
includes: light-chain deposition disease, light- and 
heavy-chain deposition disease, and heavy-chain depo-
sition disease. Kappa light-chains are more frequent in 
MiDD than in AL amyloidosis. Typical manifestation of 
renal involvement includes massive proteinuria, hae-
maturia, hypertension, and premature kidney failure 
[16, 21]. Light-chain deposition disease (LCDD) and 
AL amyloidosis have several features in common: both 
may affect the heart, liver, or peripheral nervous system 
and may cause kidney failure. Most patients with LCDD 
already present symptoms of renal failure at the time of 
initial presentation of the disease. Kidney biopsy shows 
deposits that are Congo red negative, amorphous, and 
electron dense [22]. in some situations both amyloid 
and nonfibrillar monoclonal light-chain deposits may 
be present in the same patient [20, 23].
Cryoglobulins are immunoglobulins that precipitate 
or gel reversibly at temperatures below 37°C [5]. Type 
i monoclonal cryoglobulinaemia is uncommon and is 
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characterised by the presence of igG immunoglobulin. 
The symptoms are typically caused by precipitation of 
the cryoglobulin in small vessels. Clinical presentation 
usually involves the skin (raynaud phenomenon, acro-
cyanosis, necrosis, purpura and ulcers, cold urticaria) 
or manifests as nephropathy [24]. in contrast to patients 
with type ii or type iii cryoglobulinaemia, renal involve-
ment has been described only sporadically [25]. Type 
ii cryoglobulinaemia is usually associated with hepatitis 
C virus (HCv) infection. it presents with monoclonal 
igM and coexisting polyclonal igG immunoglobulin. 
The monoclonal igM rheumatoid factors bind the FC 
portion of igG [26]. The clinical features are similar 
to those present in type i cryoglobulinaemia and also 
include purpura, neuropathy, and renal involvement. 
Additionally, weakness, arthralgia, and liver involvement 
can be observed in some patients [27].
Proliferative glomerulonephritis with monoclonal 
immunoglobulin deposits
Proliferative glomerulonephritis with monoclonal 
immunoglobulin deposits presents with a non-or-
ganised deposition of whole igG3k immunoglobulin 
particles. Typical symptoms include proteinuria and 
progressive chronic kidney disease [28]. Other organs, 
including bone marrow, are rarely affected.
Adult Fanconi syndrome
Adult Fanconi syndrome is characterised by the pres-
ence of glycosuria, aminoaciduria, hypophosphataemia, 
and vitamin D-resistant rickets. it is caused by lysosomal 
accumulation of monoclonal kappa light chains, which 
aggregate and form crystals. it can be observed in pa-
tients with plasma cell or lymphoid proliferation [5, 29]. 
These patients may suffer from recurrent bone pain. This, 
in combination with the presence of light-chains in urine it 
may in some situations result in the diagnosis of Bence-
Jones myeloma. it is therefore important to establish 
glucose levels in urine. Patients with Adult Falconi syn-
drome will have elevated glucose levels while their blood 
glucose levels remains normal [29]. Untreated disease 
may lead to kidney failure [14]. in some situations Fanconi 
syndrome can be a part of crystal-storing histiocytosis, 
with light-chain crystal accumulation in histiocytes in the 
bone marrow, spleen, and lymph nodes [30].
Treatment
elimination of monoclonal B clone
There is no standard treatment of MGrS. Targeting 
a B cell clone requires an administration of chemothera-
peutics or other medications that are used for treatment 
of lymphoid malignancies or myelomas. The choice of 
the therapeutic agent should be made according to 
kidney function. Alkylating agents, such as melphalan 
must be used with caution. when possible, melphalan 
should be replaced by cyclophosphamide, which is 
better tolerated by patients with impaired renal func-
tion [31]. in terms of immunomodulators, thalidomide 
should be used as a first-line drug before lenalidomide 
because it does not require dose reduction in patients 
with impaired kidney function [32]. Fludarabine, an ade-
nine nucleoside analogue, should be avoided in patients 
with severe renal impairment [32]. Bendamustine is not 
metabolised in the kidneys and may be given to patients 
with MGrS without modification due to renal function 
parameters [33, 34]. The use of monoclonal antibod-
ies, including anty-CD20, is safe even for patients with 
impaired renal function [35, 36]. 
in younger patients with myeloma, the standard 
procedure consists of consolidation with high-dose 
melphalan chemotherapy, followed by autologous stem 
cell transplantation. This treatment can be administrated 
to patients with severe kidney dysfunction caused by 
MGrS, but significant morbidity and mortality must be 
taken into account [37, 38].
Treatment of amyloidosis 
Treatment of amyloidosis should refer to the Mayo 
Clinic criteria [39]. The first-line treatment for patients 
in stage i and stage ii should include bortezomib, ste-
roids, and alkylating agents [40, 41]. The second-line 
treatment is based on thalidomide [42]. Certain pa-
tients can undergo a consolidation with high-dose 
melphalan chemotherapy followed by autologous stem 
cell transplantation [43, 44]. Stage iii patients present 
a therapeutic challenge because of an extremely poor 
prognosis. Administration of antibodies to serum amy-
loid P component may be a successful treatment option 
in such a difficult clinical scenario [45]. 
Monoclonal immunoglobulin deposition disease
There is no standard treatment for this condition. 
The procedures are based on consensus recom-
mendations. The majority of patients are treated with 
thalidomide or bortezomib. in some cases high-dose 
melphalan chemotherapy followed by HSCT may be 
implemented [21, 46–48]. There is a strong association 
between haematological response to chemotherapy 
and renal function [21]. Most of the patients who achieve 
a complete or partial response never require dialysis. in 
contrast, those with minimal or partial haematological 
response usually develop end-stage renal disease. 
According to the consensus recommendation, the main 
goal of the treatment for patients with early stage chronic 
kidney disease (CKD) 1–3 should be preservation of 
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kidney function. elimination of monoclonal B-clone 
should be the main target for patients with CKD 4–5, 
who are eligible for kidney transplantation. if kidney 
transplantation is not possible, the therapy should be 
aimed at preservation of extra-renal organs [16]. 
Treatment of cryoglobulinaemia
According to the recommendations for cryo-
globulinaemia, asymptomatic patients require close 
monitoring of renal parameters [16]. Symptomatic 
patients with plasmocytic proliferation of monoclonal 
igG or igA protein should be treated as myeloma 
patients. Patients with lymphoplasmocytic prolif-
eration and production of igM monoclonal protein 
should receive waldenstrom macroglobulinaemia 
type of treatment, including rituximab, and chronic 
lymphocytic leukaemia-type clone should be treated 
as is recommended for patients with this condition. 
For patients with severely impaired kidney function, 
bendamustine (which is not eliminated by kidneys) 
could be effective [25, 49, 50]. Type ii cryoglobuli-
naemia is usually caused by igM monoclonal protein 
and in most cases is linked to hepatitis C infection. 
it is recommended to introduce antiviral treatment for 
every patient with symptomatic type ii cryoglobuli-
naemia and active hepatitis [16]. For patients without 
active viral replication, a wait and watch approach is 
recommended with rituximab treatment when flares 
of the disease are observed [51].
Proliferative glomerulonephritis with monoclonal 
immunoglobulin deposits
Patients at an early stage of the disease (stage i–ii, 
proteinuria less than 1 g per day) only require ob-
servation. in more advanced stages of the disease, 
cyclophosphamide or bortezomib treatment can be 
introduced. Consolidation with high-dose melphalan 
chemotherapy with autologous stem cell transplant 
is also possible. Complete haematological remission 
is the main target of the treatment for those awaiting 
kidney transplantation [10, 16].
Adult Fanconi syndrome
Myeloma-like chemotherapy (bortezomib-, tha-
lidomide-, or cyclophosphamide-based) should be 
introduced in the early stages of the disease. The 
treatment of more advanced stages of the disease 
includes high-dose melphalan chemotherapy with au-
tologous stem cell transplantation (before or after renal 
transplantation). Only symptomatic treatment should 
be offered to patients who are not eligible for kidney 
transplantation [16]. 
response assessment
it is logical and recommended to adoptdisease 
response assessment in conditions related to light-
chain proliferation criteria introduced for amyloidosis 
assessment [16]. This system includes four levels of 
responses: complete response: normal free light chain 
ratio and negative serum and urine immunofixation, 
very good partial response (with difference between 
involved and uninvolved free-light chain < 40 mg/L), 
partial response (decrease in free-light chain > 50%), 
and no response [52]. in diseases caused by whole 
monoclonal immunoglobulin particle, assessment 
should be based on international uniform response 
criteria for multiple myeloma [16, 53]. Another rec-
ommendation is to reintroduce treatment immediately 
after the reappearance of monoclonal immunoglobulin, 
before kidney parameters decrease [16]. 
Treatment of renal failure
The treatment of renal failure should not differ from 
the treatment of other kidney conditions that are not 
related to the presence of monoclonal protein. Ac-
cording to expert opinion, monoclonal gammopathy 
is not a contraindication to kidney transplantation. 
Appropriate treatment should be introduced to achieve 
the best monoclonal protein response before the 
transplantation. The response is directly correlated to 
kidney transplant survival and should be reintroduced 
immediately after reappearance of monoclonal protein. 
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